Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, thereby blocking the interaction of this domain with the FXa active site. Injections of Concizumab increase thrombi
CAS Number:
[1312299-39-0]
Target:
NN 7415 , mAb 2021
* VAT and and shipping costs not included. Errors and price changes excepted